HOME >> MEDICINE >> NEWS
New class of targeted cancer drugs shows promise in slowing progression of recurrent prostate cancer

A new class of targeted anti-cancer drugs that blocks the human epidermal growth factor (HER) receptor family shows promise in prolonging the lives of patients with recurrent prostate cancer, a new Cedars-Sinai study shows. The drug, a molecular targeted compound called pertuzumab, works by binding to and inhibiting the function of HER2 receptors, interrupting a key pathway that leads to cancer growth.

The study, published in the February 20 issue of the Journal of Clinical Oncology, involved 41 patients with treatment-resistant prostate cancer who had experienced progression of their disease after prior chemotherapy. Patients received the drug every three weeks until disease progression. MRI and CAT scans were used to evaluate the tumors during the period of drug therapy. While no shrinkage of tumors was reported, retrospective analysis showed that survival rate was prolonged to 16.4 months with the drug as compared to a median average of 10.7 months in a historical control group with similar baseline prognostic features.

Advanced prostate cancer is difficult to treat and the drug therapies currently available to these patients have not been very effective, especially in patients whose disease has progressed after chemotherapy treatment, said David B. Agus, M.D., principal investigator of the study and research director of Cedars-Sinais Louis Warschaw Prostate Cancer Center at the Samuel Oschin Comprehensive Cancer Institute. Pertuzumab may offer a new treatment approach for these patients when it is evaluated as a tool to slow not stop or shrink -- tumor growth.

The theory is that by significantly slowing progression of the cancer, patients will experience a good quality of life for a longer period of time, said Agus. Ultimately, we hope drugs like pertuzumab will help us reach the point where cancer can be viewed as a lifetime disease to be managed much like AIDS is looked at now. This would be major shift from the current
'"/>

Contact: Simi Singer
simi.singer@cshs.org
310-423-4768
Cedars-Sinai Medical Center
16-Feb-2007


Page: 1 2 3

Related medicine news :

1. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
2. Early-morning Friday classes may prevent students from getting sloppy on thirsty Thursdays
3. Panel offers guidelines on skin reactions to new class of cancer drugs
4. UK researchers find new class of nontoxic cancer treatments
5. New class of HIV drug attacks previously untargeted enzyme
6. Sleep disturbances affect classroom performance
7. Simple classification can help define and predict limb-threatening diabetic infections
8. World-class Biomedical Research Center to be in West London
9. A new way of classifying addictive drugs
10. Phys ed class more effective when theres more talking
11. W.M. Keck Foundation announces 2006 class of Distinguished Young Scholars in Medical Research

Post Your Comments:
(Date:8/29/2015)... ... 2015 , ... "I have been a licensed physical therapist ... in manual therapy, and my invention will provide headache sufferers a solution to ... dysfunction throughout the body." , They developed THE RELIEVER to alleviates headaches, as ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... extend and improve the lives of patients, according to a newly published report. ... to read the full article. , The authors of the new paper ...
(Date:8/29/2015)... ... 29, 2015 , ... Brands like Toppik , Eau Thermale Avene and ... “Before, a threshold of $49.00 was required to qualify for free standard shipping,” said ... standard shipping for customers regardless of the item’s selling price.” , With competitive pricing ...
(Date:8/29/2015)... CA (PRWEB) , ... August 29, 2015 , ... ProDrop ... X . Each preset contains 15 seconds of unique footage that users can shrink ... rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, ...
(Date:8/29/2015)... , ... August 29, 2015 , ... ... include treating the localized area with stretching, soft tissue manipulation. Platelet rich plasma ... position have shown through research to improve treatment outcomes. This localized treatment ...
Breaking Medicine News(10 mins):Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Originally discovered by Welfide (Mitsubishi ... Industries, Ltd) as an inflammatory drug, pranoprofen was ... Co., Ltd under the trade name of pranopulin ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Quetiapine Market, ... Developed by AstraZeneca plc, quetiapine (under the trade ... the treatment of schizophrenia. Approved by CFDA to ... the Catalogue of Drugs for the Basic National ...
Breaking Medicine Technology:Investigation Report on China's Pranoprofen Market, 2010-2019 2Investigation Report on China's Tobramycin Market, 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2
Cached News: